Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable

2.1 Daratumumab (Darzalex, Janssen–Cilag) in combination with bortezomib, thalidomide and dexamethasone, is indicated 'for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant'.

2.2 The dosage schedule is available in the summary of product characteristics for daratumumab.

2.3 The list price for daratumumab is £4,320 per 1,800‑mg vial of solution for injection intended for fixed-dose subcutaneous administration (excluding VAT; BNF online, accessed November 2021). It is also available as a concentrate for solution for intravenous infusion with a list price of £360 per 100‑mg vial, and £1,440 per 400‑mg vial (excluding VAT; BNF online, accessed November 2021). The company has a commercial arrangement. This makes daratumumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

2.4 The list price for bortezomib is £762.38 per 3.5‑mg vial (excluding VAT; BNF online, accessed November 2021). There is a discount for bortezomib agreed with the Commercial Medicines Unit. The prices agreed through the framework are commercial in confidence.

2.5 The list price for thalidomide is £298.48 per 28‑pack of 50 mg capsules (excluding VAT; BNF online, accessed November 2021).

2.6 There is a nationally available discount for dexamethasone with the Commercial Medicines Unit. The prices agreed through the framework are commercial in confidence.